STOCK TITAN

Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Journey Medical , a pharmaceutical company specializing in dermatological products, will announce its first quarter 2024 financial results on May 13, 2024. The company will host a conference call to discuss the results and provide a corporate update at 4:30 p.m. ET on the same day.

Positive
  • None.
Negative
  • None.

Company to host conference call to discuss financial results and provide a corporate update on May 13, 2024 at 4:30 p.m. ET

SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2024 financial results after the U.S. financial markets close on Monday, May 13, 2024. Journey Medical management will conduct a conference call and audio webcast on Monday, May 13, 2024 at 4:30 p.m. ET.

To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the Journey Medical conference call. Participants can register for the conference by navigating to https://dpregister.com/sreg/10188768/fc6df642e0. Please note that registered participants will receive their dial-in number upon registration.

A live audio webcast can be accessed on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com, and will remain available for replay for approximately 30 days after the conference call.

About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The company currently markets seven branded and two generic products that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.

Company Contact:
Jaclyn Jaffe
Journey Medical Corporation
(781) 652-4500
ir@jmcderm.com

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com  


FAQ

When will Journey Medical announce its first quarter 2024 financial results?

Journey Medical will announce its first quarter 2024 financial results on May 13, 2024.

What time will the conference call to discuss the financial results be held on May 13, 2024?

The conference call to discuss the financial results will be held at 4:30 p.m. ET on May 13, 2024.

How can interested parties listen to the conference call?

Interested parties within the U.S. can dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international) to listen to the conference call.

Where can participants register for the conference call?

Participants can register for the conference call by navigating to https://dpregister.com/sreg/10188768/fc6df642e0.

Journey Medical Corporation

NASDAQ:DERM

DERM Rankings

DERM Latest News

DERM Stock Data

113.22M
16.35M
30.48%
14.64%
0.29%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
SCOTTSDALE